Journal of Thoracic Oncology
Издатель: Elsevier · ISSN 1556-0864 · 84 статей
- IASLC Multidisciplinary Recommendations for Assessment and Reporting of Lymph Node Treatment Response in Lung Cancer Resection Specimens After Neoadjuvant Therapy
- Global Practices in the Diagnosis and Management of Thymic Epithelial Tumors: An International Thymic Malignancy Interest Group Survey and Multidisciplinary Discussion
- Nivolumab Plus Ipilimumab as First-Line Treatment for Patients With Metastatic Non–Small Cell Lung Cancer: Final, 7.5-Year Outcomes From CheckMate 227
- Artificial Intelligence in Thoracic Pathology and Biomarker Assessment: An IASLC Pathology Committee Review
- Disease Kinetics and Practice Patterns in More Than or Equal to 4-Year Long-Term Beneficiaries of Immune Checkpoint Inhibitors for Advanced NSCLC
- Comprehensive Patient-Reported Outcomes from NRG Oncology/Alliance LU005: A Randomized Trial of Chemoradiation With or Without Atezolizumab in Limited-Stage SCLC
- Bridging Evidence and Practice: International Multidisciplinary Consensus on Non-Metastatic NSCLC
- Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Brief Report
- Prognostic Significance of Spread Through Air Spaces in Stage Ia/bN0 NSCLC—An Evaluation in the JCOG0802/WJOG4607L Clinical Trial Patients
- Sutetinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial
- DNA and RNA EGFR Variant Allele Fractions and Clinical Outcomes in Lung Adenocarcinoma
- Pulmonary Toxicities of Antibody-Drug Conjugates in SCLC and NSCLC: A Systematic Review and Meta-analysis
- Lymph Node Pathologic Grading Strategy: Under the Backdrop of the IASLC Grading System for Invasive Lung Adenocarcinoma – A Retrospective Cohort Study Among Asian Patients
- Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA NSCLC: Exploratory 8-Year Overall Survival Landmark Update from the ADAURA Trial
- Integrated Multi-Omic Profiling Enables Recurrence Risk Stratification Beyond Pathological Stage in Resected EGFR-Mutant Lung Adenocarcinoma
- Genomic and Transcriptomic Features of Relapsed SCLC
- Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced NSCLC in a Phase 2 Study
- Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy
- Grade 3 Lung Carcinoids/NETs: The IASLC Pathology Committee Study with Proposal of a New Diagnostic Category
- Validation of the Sybil Lung Cancer Risk Prediction Model in a Predominantly Black Screening Cohort: A Brief Report
- Efficacy and Safety of HER2-Directed Therapies for Advanced HER2-Mutant NSCLC: A Systematic Review and Meta-Analysis
- Gene-Specific Analysis of Clonal Hematopoiesis Identifies the Association Between ASXL1 and Lung Cancer Risk
- Tobacco News Update-From the IASLC Tobacco Control Committee
- Significant by Chance: Revisiting the Evidence for Segmentectomy
- No Longer a Luxury? MRD Dynamics as the Final Arbitrator for Cure in Locally Advanced NSCLC
- Large Cell Neuroendocrine Carcinoma: Rethinking the Path to Better Therapies
- Beyond BMI: Is Visceral Adiposity Reframing the Obesity Paradox in Lung Cancer?
- Advances in Pathology: Journal of Thoracic Oncology 20th Anniversary Series
- Emerging Targeted Therapies for HER2-Mutant NSCLC
- IASLC Update on Classification of Pulmonary Neuroendocrine Neoplasms